KdT Ventures has announced the successful close of its oversubscribed fourth fund (Fund IV), raising over $100 million to support early-stage, science-driven companies. This marks the firm's largest fund to date, surpassing its previous $80 million Fund III from 2022. With this new capital, KdT Ventures now manages over $250 million in assets.

“Scientific breakthroughs are rapidly transforming our physical world, and we remain committed to backing the most ambitious founders who are harnessing these advances to build groundbreaking companies,” said Cain McClary, M.D., Founder and Managing Partner of KdT Ventures. “Our investments target technical founders who are leveraging cutting-edge chemistry, biology, compute and other scientific disciplines to create revolutionary products and technologies.”

KdT will continue its focus on companies applying cutting-edge technologies across a range of sectors, including therapeutics, digital health, industrial biotechnology, and climate, at the earliest stages of development. Unlike many venture firms that have shifted towards larger funds requiring bigger, later-stage investments, KdT remains dedicated to its mission of supporting scientific innovations from the ground up.

“Our team’s unique scientific and operational experience provides strategic insights at inception to maximize the potential of technological platforms across the diverse verticals covered by the firm,” said Phil Grayeski, Ph.D., Managing Partner at KdT Ventures. “In practice, we’ve repeatedly demonstrated our ability to find and support disruptive companies across each vertical of focus.”

KdT often serves as the first institutional investor in a company, making initial investments that range from $500,000 to $5 million. The firm also has the flexibility to evaluate later-stage opportunities by leveraging its institutional investor base to support larger investments.

“Our approach has always been to find and support entrepreneurs who are solving complex challenges by leveraging the convergence of computational tools and science,” said Mack Healy, J.D., Managing Partner at KdT Ventures. “With our deep technical expertise, outsized team, and relentless desire to be the best early stage science firm, we’re well positioned to provide the hands-on support that founders need to build transformative companies.”

In line with its expansion, KdT has announced two key promotions:

• Phil Grayeski, Ph.D., has been promoted to Managing Partner. Grayeski has been integral to shaping KdT's investment strategy since Fund I in 2018 and has extensive experience in biotechnology and genetic medicine. He has been involved in founding several biotech companies, including Torque Bio, StrideBio, and Ribometrix.
• Patrick Malone, M.D., Ph.D., has been promoted to Partner. Malone brings expertise in neuroscience and machine learning and began his investment career at Northpond Ventures.

Founded by Cain McClary in 2017, KdT Ventures boasts an investment team known as "Scientific Athletes," with nine advanced degrees and 48 years of combined scientific and clinical training. The firm's portfolio, which now includes over 65 companies, spans multiple supply chains and industries, allowing KdT to offer deep technical and strategic support to a select number of early-stage investments each year, fostering their growth.